The Cleveland-based regenerative medicine company that is preparing for commercialization of its MultiStem cell therapy named Daniel A. Camardo as CEO, effective Feb. 14. He also will join the company's board of directors. William (B.J.) Lehmann, who has been interim CEO at Athersys for nearly a year, will return to the roles of president and chief operating officer, which he held prior to the interim appointment.